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Abstract
Background—Adverse event (AE) reporting in oncology trials is required, but current practice 
does not directly integrate the child’s voice. The Pediatric Patient-Reported Outcomes version of 
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the Common Terminology Criteria for Adverse Events (PRO-CTCAE) is being developed to 
assess symptomatic AEs via child/adolescent self-report or proxy-report. This qualitative study 
evaluates the child’s/adolescent’s understanding and ability to provide valid responses to the PRO-
CTCAE to inform questionnaire refinements and confirm content validity.
Procedure—From seven pediatric research hospitals, children/adolescents ages 7–15 years who 
were diagnosed with cancer and receiving treatment were eligible, along with their parent-proxies. 
The Pediatric PRO-CTCAE includes 130 questions that assess 62 symptomatic AEs capturing 
symptom frequency, severity, interference, or presence. Cognitive interviews with retrospective 
probing were completed with children in the age groups of 7–8, 9–12, and 13–15 years. The 
children/adolescents and proxies were interviewed independently.
Results—Two rounds of interviews involved 81 children and adolescents and 74 parent-proxies. 
Fifteen of the 62 AE terms were revised after Round 1, including refinements to the questions 
assessing symptom severity. Most participants rated the PRO-CTCAE AE items as “very easy” or 
“somewhat easy” and were able to read, understand, and provide valid responses to questions. A 
few AE items assessing rare events were challenging to understand.
Conclusions—The Pediatric and Proxy PRO-CTCAE performed well among children and 
adolescents and their proxies, supporting its content validity. Data from PRO-CTCAE may 
improve symptomatic AE reporting in clinical trials and enhance the quality of care that children 
receive.
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1 | INTRODUCTION
In 2016, over 10,000 children under 15 years of age will be diagnosed with a new cancer in 
the United States.1 Contrary to low clinical trial participation rates in adults, over 60% of 
children and adolescents with cancer participate in a trial.2 Enrollment in clinical trials at 
initial diagnosis has become the standard of care in pediatric oncology in the United States.3
It is mandatory in clinical trials that adverse events (AEs) be collected and reported. In 
oncology, the lexicon for AE grading is the National Cancer Institute’s Common 
Terminology Criteria for Adverse Events (CTCAE), which consists of 790 AE terms.4 While 
many AEs are graded based on laboratory values or clinical measurements, 62 AEs are 
symptoms (e.g., pain, fatigue, depression) that are subjective in nature.5 Evidence from 
multiple studies suggests that clinicians’ and parents’ ratings of children’s symptoms do not 
reflect children’s self-reported experiences.6–12 Specifically, previous studies have found 
poor agreement between what children and parents/clinicians report, with parents/clinicians 
more often underreporting the burden of cancer and treatment on the lives of the children 
and adolescents.6,7,9,10 Even worse, AE grading is based on what is documented in patient 
charts and symptoms are thus more likely missed compared with clinical or laboratory 
results.13 Despite these important findings, clinicians continue to routinely grade 
symptomatic AEs in pediatric oncology trials.
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Our overall study is designed and seeks to validate a system for children and adolescents to 
self-report on the symptomatic AEs they experience while undergoing cancer treatment. The 
endgoal is to enhance the precision of AE grading in pediatric oncology trials and improve 
the healthcare for the children. This study extends previous work initiated by the NCI to 
design the Patient-Reported Outcomes version of the CTCAE (PRO-CTCAE) for adults in 
oncology trials.14–16 The PRO-CTCAE system is different from the standard outcome 
measures used in research, such as the Patient-Reported Outcomes Measurement 
Information System® (PROMIS®), in that it screens patients over a broad range of symptom 
toxicities with the goal of informing CTCAE grading. Compared with other PRO measures, 
the PRO-CTCAE uses a small set of questions to identify the worst severity, frequency, and 
interference of symptom toxicities on the daily lives of trial participants. Envisioned use of 
the PRO-CTCAE includes AE detection/screening, support of dose-finding work, and 
assessment of comparative tolerability for product labeling claims.16
Based on our previous study among 187 pediatric clinicians from seven pediatric cancer 
centers, the draft pediatric and proxy versions of the PRO-CTCAE were designed to assess 
up to 62 symptomatic AEs.5 The main goal of this cognitive interview study was to 
establish, evaluate, and refine the PRO-CTCAE measures to be comprehensible to children 
and their caregivers and relevant for capturing AEs. The second goal was to stratify children 
into different age groups that represent different developmental stages to determine if 7–8-
year-old children can understand and respond to the Pediatric PRO-CTCAE and at what age 
can adolescents transition to the already developed Adult PRO-CTCAE measure. Cognitive 
interviewing is a necessary step in the design and validation of a PRO measure17 and 
recommended by the Food and Drug Administration.18
2 | METHODS
2.1 | Participants and setting
Seven pediatric research hospitals participated: Children’s Hospital Los Angeles, Children’s 
National Health System (Washington, District of Columbia), Hospital for Sick Children 
(Toronto, Ontario, Canada), Dana-Farber Cancer Institute and Boston Children’s Hospital, 
Palmetto Health Children’s Hospital (Columbia, South Carolina), St. Jude Children’s 
Research Hospital (Memphis, Tennessee), and the University of North Carolina (UNC). 
These sites provided access to a diverse population of children in terms of demographics, 
cancer types, and treatment modalities. The UNC was the coordinating center. All sites 
received approval from their institutional review boards.
Children and adolescents ages 7–20 years who were diagnosed with a cancer of any type and 
receiving treatment within or outside the context of a clinical trial were eligible to 
participate. The child’s parent or caregiver (from here on referred to as “proxy”) must be at 
least 18 years of age to participate. Also, both the children and proxies must be able to speak 
English and to report their/their children’s symptom AEs. Ideally, both the child and her/his 
proxy should participate in the study; however, there were a limited number of times when 
only the child or the proxy participated, based on their preference. Participants ages 18 years 
or older provided their own signed consent and children younger than 18 years provided the 
assent.
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2.2 | Measures
The Pediatric and Proxy versions of the PRO-CTCAE consist of a library of items to assess 
up to 62 symptomatic AEs included in the CTCAE. Based on the research team’s expertise 
in survey design and review of the literature, CTCAE medical terminology was translated 
into child-friendly terms (e.g., epitaxis = nose bleeds). Questions were developed to capture 
the child’s symptom experience. For a given AE, one to three questions were created to 
reflect attributes of the symptom experience including frequency, worst severity, interference 
with daily activities, or presence. Table 3 provides examples of each of these question types. 
In total, 130 questions were drafted for the Pediatric PRO-CTCAE. The Proxy version 
mirrored the child self-report version except “you” was replaced with “your child.” The 
Adult PRO-CTCAE was tested among 13–15- and 16–20-year-olds in Round 1; findings of 
the Adult PRO-CTCAE are reported elsewhere.
The selected reference period for the Pediatric PRO-CTCAE questions balanced the need to 
minimize both recall bias (from long periods of memory) and burden from the child having 
to complete numerous repeated assessments to ensure there was no missing time gap in a 
longitudinal study. “In the past 7 days” was selected as the reference period, consistent with 
other validated pediatric PRO measures.19,20
2.3 | Cognitive interviewing procedures
One-on-one interviews with the child/adolescent and the proxy had two parts. The first part 
elicited concepts and terminology from participants in a free-form format (i.e., without 
viewing the questionnaire). Participants were asked to discuss symptoms and other health 
concerns they had experienced in the last 7 days. Results from the concept-elicitation phase 
are published elsewhere and the language used by the children to describe symptoms in the 
free-form format informed the refinement of the Pediatric PRO-CTCAE questions tested in 
Round 2 of interviews.21 The second part of the cognitive interviews evaluated the draft 
Pediatric and Proxy PRO-CTCAE questionnaires using semistructure interview probes. 
Probes included questions such as, “How would you describe <symptom>?” or “In your own 
words, what do you think this question is asking?” Through this process, we obtained the 
feedback on the wording of the items, response options, and reference period.
We stratified interviews by age group (7–8, 9–12, 13–15, and 16–20 years) to represent 
distinct developmental stages. We performed two rounds of cognitive interviews. In Round 
1, participants aged 7–12 years and their proxies completed the Pediatric or Pediatric-Proxy 
PRO-CTCAE. Participants aged 13–20 years and their proxies completed the Adult or 
Adult-Proxy PRO-CTCAE. Because of challenges understanding the Adult PRO-CTCAE 
measure in Round 1, the 13–15-year-old group completed the Pediatric PRO-CTCAE 
measures in Round 2.
In Round 1, children and proxies evaluated the 62 PRO-CTCAE symptom AEs (130 
questions). To reduce respondent burden, we divided the 62 AEs among four forms with the 
goal of having at least six participants in each age group complete each form. Sample sizes 
of six participants per item are consistent with the sample sizes recommended by the NIH’s 
PROMIS initiative22 and other guidelines for conducting cognitive interviews.17,23
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Round 2 aimed to review items that were substantially revised based on findings from 
Round 1. Items are defined as being “substantially revised” if their revision involved the 
following: (i) adding or removing a word(s) that changed the meaning of a phrase; (ii) word 
substitutions that in the judgment of the investigators were more than a semantic 
simplification; or (iii) significant changes to the response options. In Round 2, 21 AEs (48 
questions) were evaluated using two questionnaires.
We employed a retrospective probing method for cognitive interviews,23 in which 
participants first completed a paper questionnaire on their own and were then asked by 
trained interviewers to explain their responses to particular items (Fig. 1). When possible, 
children and proxies were interviewed in separate spaces so as to not influence the other’s 
responses. During questionnaire completion, participants were asked to mark items they 
found hard to understand. As participants completed the questionnaires, the interviewers 
noted in their field notes if help or clarification was given. Although participants were 
encouraged to complete the questionnaires individually, interviewers assisted children in 
reading the items, when necessary. Upon the completion of the interviews, each participant 
received a $25 gift card.
To standardize procedures and ensure consistency across sites, interviewers were trained 
during a 1-day, in-person workshop led by a cognitive interview methods expert. Prior to the 
initiation of Round 2, all interviewers received a refresher training. Interviewers and site 
lead investigators participated in weekly team calls to discuss interview experiences, 
findings, recommendations, and ongoing recruitment progress.
2.4 | Analytic approach
With consent from the proxy and child, each cognitive interview was digitally audio-
recorded. Recordings were transcribed by a professional service. In addition, the 
interviewers wrote detailed field notes during and after the interviews to aid in the 
preparation of an interview summary. Following the completion of a cognitive interview, the 
interviewers entered the data into a REDCap database. In REDCap, the interviewers 
reported on child and proxy demographics, item-by-item responses to each question 
including items participants marked as hard to understand. Additional interviewer comments 
regarding participant’s body language, facial expressions, perceived attitude, problems 
raised, and interview duration were also entered into REDCap.
Interview notes and participant responses were organized by each AE item to summarize 
participants’ experiences with the PRO-CTCAE questionnaire. Upon completion of each 
round, representatives from participating sites, including interviewers, physicians, nurses, 
and PRO methodologists, reviewed the summarized the data by age group to evaluate the 
participants’ understanding of the AE items, question stems, response options, and 
instructions. This process included reviewing participant-marked hard to understand items 
and items that interviewers identified (through discussion) as hard to understand. Transcripts 
were further reviewed to inform findings. When assessing comprehensibility, more weight 
was given to items when more than one child had difficulties with the item; however, all 
questions were discussed. Overall summaries were created and approved by representatives 
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from each site, including recommendations of modifications and approval of items for the 
final version of the questionnaire.
3 | RESULTS
3.1 | Participant characteristics
In Round 1, 54 children (7–12-year-olds) were approached, nine refused and 45 children and 
42 proxies participated in the interviews. Twenty children were in the 7–8-year-old group 
and 25 were in the 9–12-year-old group (Table 1).
For Round 2, 51 children and adolescents were approached and 15 refused. Thirty-six 
children and adolescents and their proxies participated (12 in each age group 7–8, 9–12, and 
13–15 years) to evaluate “substantially revised” items and the revised symptom severity 
phrasing. Smaller samples participated in Round 2, as fewer questions were evaluated; 
however, our minimum of six children reviewing each item was maintained.
3.2 | Assessment of symptom AE terms
Round 1 included 7–8- and 9–12-year-olds evaluating the Pediatric PRO-CTCAE. Of the 62 
AE terms evaluated, at least one 7–8-year-old experienced difficulty with 20 AE terms; 
however, only six of the 20 had two or more children experiencing difficulties, such as 
knowing what the terms meant or accurately defining it in their own words. Among the 9–
12-year-olds, at least one child had difficulties with 22 AE terms; 13 of the 22 identified 
items had two or more children having difficulty. Within the 9–12-year-old group, 9- and 10-
year-olds had greater difficulties compared with 11- and 12-year-olds. Online 
Supplementary Table S1 identifies the AE terms from Round 1 that were revised and 
evaluated in Round 2.
Round 2 included 7–8-, 9–12-, and 13–15-year-olds evaluating the items revised or needed 
further review by more children. Of the 21 AE terms included in Round 2, 13 had at least 
one 7–8-year-old who experienced difficulty with the term. Nine of the 13 identified items 
had two or more children having difficulty. Among the 9–12-year-olds, at least one child had 
difficulties with nine AE terms, but two or more children had difficulty with two of these 
nine terms. Among the 13–15-year-olds, only three items were hard to understand by one or 
more adolescents, and two or more adolescents had difficulty with two of these three items. 
Final wording of the AE terms are given in Table 2.
3.3 | Assessment of question structure and response options
In Round 1, children and adolescents had no difficulty in reading and providing responses to 
questions related to AE frequency, presence, or interference. However, the severity stem 
(How bad was the worst <symptom>?) was challenging across both 7–8 and 9–12 age 
groups. Children had difficulty describing the concept of the “worst” symptom experience 
and preferred discussing symptom severity in terms of how “bad” the symptom was. Also, 
children in both age groups interchanged concepts of frequency and interference when 
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article.
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describing severity and the corresponding response options. As such, we changed the 
severity stem in Round 2 to reflect the preference for “bad” to express severity. We also 
changed one response option (from “Alittle” to “Alittle bad”) to better flow with the severity 
stem change. In Round 2, the new severity stem and response options were well understood 
across the three age groups. Final wording of the question types is given in Table 3.
3.4 | Assessment of recall period
In general, among 9–12-year-olds (Rounds 1 and 2) and 13–15-year-olds (Round 2), 
children/adolescents did not have any challenges with the 7-day reference period. Although 
some children described longer and some described shorter than the specified recall periods, 
most of them accurately defined a 7-day period. Among the youngest age group (7–8-year-
olds), the reference period was generally a difficult concept in both rounds, with many 
children not accurately defining the appropriate recall period.
3.5 | Children’s overall rating of survey
Generally, the 7–8- and 9–12-year-olds had an easy time completing the Pediatric PRO-
CTCAE instrument in both Rounds 1 and 2. Of the 45 children aged 7–12 years who 
participated in Round 1, 23 described it as “very easy,” 18 as “somewhat easy,” and four as 
“somewhat hard” to answer most of the questions. The four children who marked it as 
“somewhat hard” were in the 7–8-year-old group. Of the 24 children who were 7–12 years 
old in Round 2, 15 marked the questionnaire as “very easy,” seven marked as “somewhat 
easy,” and two as “somewhat hard.” Both of the children who marked the questionnaire as 
“somewhat hard” were in the 7–8-year-old group. Of the 12 adolescents (13–15-year-olds) 
in Round 2, eight marked the questionnaire as “very easy” and four as “somewhat easy.”
3.6 | Proxy findings
3.6.1 | Round 1—Of the 42 proxies who completed the Proxy PRO-CTCAE measure, 31 
described it as “very easy” and 11 as “somewhat easy” to answer most of the questions. Of 
the 63 AEs assessed in Round 1, 13 AEs were identified as difficult by at least one proxy. Of 
these 13 AEs, only three had at least two proxies experiencing difficulties with. Proxies 
found certain AEs including “flashing lights,” “swollen belly,” and “hot flashes” difficult to 
understand, which were also the three AEs that the largest number of 7–12-year-old 
participants reported having difficulty understanding.
Similar to their children, proxies had some difficulty with the severity stem, interchanging 
the concept with both frequency and interference. However, both the interference and 
frequency stems seemed to work well. Most proxies had no trouble describing the 7-day 
reference period.
3.6.2 | Round 2—In Round 2, 32 proxies participated in cognitive interviews, with 21 
participants describing the questionnaire as “very easy” and 11 as “somewhat easy.” Of the 
21 AEs evaluated in the second round, eight were identified as difficult to understand by at 
least one proxy participant. Of these eight items, four (wheezing, tinnitus, hot flashes, and 
flashing lights) had at least two participants experiencing difficulties with. Overall, the 
revised severity stem worked well in Round 2.
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4 | DISCUSSION
This cognitive interview study represents a critical step in the refinement and content 
validation of the Pediatric and Proxy PRO-CTCAE.17 Most questions in the Pediatric and 
Proxy PRO-CTCAE library were well understood by the child and adolescent participants, 
and their proxies.
This study revealed important age-related findings relevant for the application of PRO 
measures in the clinical research. Younger children experienced greater difficulties for some 
types of questions. While the majority of 7-year-olds (nine of 13) and eight of the 19 8-year-
olds needed assistance from the interviewer to read the questionnaire to them, older children 
did not need this help. Results may have differed for children having the questionnaire read 
to them; however, we believe they are still able to self-report their symptom experiences. 
Younger children also interpreted terms used in questions more literally than older children 
did, see AEs of abdominal distention and flashing lights (eye disorder) in online 
Supplementary Table S1 for examples.
Another age-related issue was the 7-day reference period. A majority of the 7–8-year-olds 
had difficulty describing what “In the past 7 days” meant. Older children typically counted 
off the days of the week, while many of the youngest would only list a few days. This 
finding is consistent with prior studies’ findings that declarative memory is less developed in 
7–8-year-olds than in older children.24,25 Future evaluation of the Pediatric PRO-CTCAE in 
younger age groups may consider shortening the reference period, as younger children 
cognitively may struggle with the concept of time.
There were some symptomatic AE terms that were difficult for participants (child or parent) 
to understand if they had not personally experienced the symptom. However, children and 
proxies who had experienced the symptom did not struggle to understand what concepts we 
were referring to and felt that the questions were worded correctly. For example, flashing 
lights was an AE that was not understood by many participants, but in Round 2 of cognitive 
interviews, we interviewed children who had experienced this symptom and approved of the 
wording. We relied on these children’s experiences when deciding on the final wording of 
the questions. For each question in the Pediatric PRO-CTCAE, we believe that if a patient 
has experienced the AE they would be able to accurately report it with the current wording. 
In addition, the library is structured so that participants would only be administered items in 
specific studies where the AE is expected.
This study had limitations. While the sample sizes are consistent with the recommended 
guidelines,22,23 we lacked adequate representation in key subgroups including children with 
central nervous system tumors. We likely did not interview the sickest of the children, as in-
depth interviewing would have been too difficult for the child to maintain his or her focus. In 
addition, because our sample was limited to children undergoing treatment, several children 
were ill and fatigued, which may have limited their full attention during the interviews. To 
reduce respondent’s burden and facilitate participation, we included breaks and provided all 
participants with a squeeze toy. Although children out of treatment may have been more 
attentive, we wanted participants that were similar to children who would complete the 
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Pediatric PRO-CTCAE in the future (i.e., those in a clinical trial). In addition, these children 
in our study were better able to describe AE symptoms because they had recently undergone 
treatment and experienced symptoms as a result. Finally, some children preferred to have 
their parents in the room during the interview, which could have impacted their responses.
This study is one of the first to employ cognitive interviewing in such a large sample of 
children undergoing cancer treatment. We also stratified interviews by age group to ensure 
representation among all ages of children, and this design allowed us to interview a number 
of 7- and 8-year-olds. Participants were diverse in terms of race/ethnicity, geography, gender, 
cancer type, treatment protocol, and treatment setting. Additionally, all of the cognitive 
interview audio recordings were transcribed, which contributed to consistent and thorough 
data analysis.
As a result of two rounds of cognitive interviewing, the Pediatric and Proxy PRO-CTCAE 
performed well, especially among older children in our study. When a 9-year-old girl was 
asked about why she said the survey was “very easy,” she responded, “Because it was 
mainly stuff about myself and I know everything about myself.” Questions on prevalent 
symptoms such as fatigue, depression, pain, headache, vomiting, and cough were well 
understood, as well as those on the less-common ones like dry skin or dizziness. This study 
served as an exploration into the ability of children at different developmental stages to be 
able to read, understand, and report on symptoms included in the PRO measures. As such, 
this study will inform future self-reported symptom assessments of children in clinical trials. 
Our next steps are to assess the construct validity of the Pediatric and Proxy PRO-CTCAE 
measures in a longitudinal multisite study. This will allow us to evaluate the instrument’s 
ability to detect changes in symptom status over time and compare self-report AEs with 
relevant clinical anchors. The availability of the Pediatric PRO-CTCAE measures will 
improve the way symptomatic AEs are reported and graded in clinical trials and enhance the 
quality of care that children receive by making providers more aware of problematic 
symptoms children are experiencing.
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FIGURE 1. 
Flow of cognitive interviews for participants
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TABLE 2
Final wording of Pediatric PRO-CTCAE symptomatic adverse event terms
Arms and legs feel weak/
weakness
    in your arms and legs
Feeling tired Pain in your mouth or throat Sad or unhappy feelings
Bigger belly than usual Food or drink taste different than
    usual
Pain or burning when you pee Flashes of light that were not 
there
    when your eyes were open or
    closed
Bruise easily (get black 
and blue
    marks on your skin)
Hair fall out Pee more than usual See blurry (have blurry vision)
Burning feeling in your 
chest (heart
    burn)
Head hurt (headache) Pee yourself on accident Shaking chills
Change in the color of 
your pee
Hiccups Pimples (bumps on the face or chest) Sneezing
Changes in your voice Hoarse (scratchy) voice Poop yourself on accident Sore throat
Cough Itchy red bumps on your skin Problems breathing (shortness of
    breath)
Stomach pain
Dizziness Itchy skin Problems remembering things Sunburn more easily
Dry eyes Muscles hurt Problems sleeping (trouble falling or
    staying asleep)
Sweat more than usual or sweat 
for
    no reason
Dry mouth Nose bleeds Problems with not being able to
    poop
Think about hurting yourself
Dry skin Not being able to sit still Problems with paying attention
    (focusing on TV, reading, or school
    work)
Throw up
Fall down Not want to eat your meals Problems with swallowing Watery eyes (tearing)
Fart more than usual Numbness or tingly feeling in your
    hands or feet
Puffiness (swelling) in your arms,
    hands, legs, or feet
Wheezing (a whistling noise in 
your
    chest when you breathe)
Feel hot all of a sudden 
(hot flashes)
Open sores or red spots on your skin Racing heart beat Worried or nervous feelings
Feel like you could not 
wait to pee
Pain Ringing or buzzing in your ears
Feeling sick to your 
stomach
    (nausea)
Pain in any bendable part of your
    body (knees, ankles, shoulders, or
    fingers)
Runny or watery poop
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TABLE 3
Final wording of Pediatric PRO-CTCAE question stems
Attribute Sample question Response options
Frequency In the past 7 days, how often did your head hurt
    (headache)?
Never/sometimes/most of the time/almost all the time
Severity In the past 7 days, how bad was your sore throat? Did not have any/a little bad/bad/very bad
Interference In the past 7 days, how much did your itchy skin keep
    you from doing things you usually do?
Not at all/some/a lot/a whole lot
Presence In the past 7 days, did you have any changes in your
    voice?
Yes/no/I do not know
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